Cargando…

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human Factor VII (fVII) as the targeting domain, fused to human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocco, E, Hu, Z, Richter, C E, Bellone, S, Casagrande, F, Bellone, M, Todeschini, P, Krikun, G, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Buza, N, Pecorelli, S, Lockwood, C J, Santin, A D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966612/ https://www.ncbi.nlm.nih.gov/pubmed/20700124 http://dx.doi.org/10.1038/sj.bjc.6605760

Ejemplares similares

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF(c )chimeric protein targeting tissue factor
por: Cocco, Emiliano, et al.
Publicado: (2011)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

IgGFc-binding protein in pregnancies complicated by spontaneous preterm delivery: a retrospective cohort study
por: Stranik, Jaroslav, et al.
Publicado: (2021)

The IgGFc-binding protein FCGBP is secreted with all GDPH sequences cleaved but maintained by interfragment disulfide bonds
por: Ehrencrona, Erik, et al.
Publicado: (2021)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
por: Cocco, Emiliano, et al.
Publicado: (2010)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

IgGFc-binding protein and MUC2 mucin produced by colonic goblet-like cells spatially interact non-covalently and regulate wound healing
por: Gorman, Hayley, et al.
Publicado: (2023)

The Rat IgGFcγBP and Muc2 C-Terminal Domains and TFF3 in Two Intestinal Mucus Layers Bind Together by Covalent Interaction
por: Yu, Hao, et al.
Publicado: (2011)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID
por: Bellone, Stefania, et al.
Publicado: (2023)

Volatility impacts on the European banking sector: GFC and COVID-19
por: Batten, Jonathan A., et al.
Publicado: (2022)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
por: Perrone, Emanuele, et al.
Publicado: (2020)

Assemblée générale du Groupe des Français du CERN (GFC)
por: CERN. Geneva
Publicado: (2014)

Assemblée générale du Groupe des Français du CERN (GFC)
por: CERN. Geneva
Publicado: (2013)

Correction to: Volatility impacts on the European banking sector: GFC and COVID-19
por: Batten, Jonathan A., et al.
Publicado: (2022)

Comparing COVID-19 with the GFC: A shockwave analysis of currency markets
por: Gunay, Samet
Publicado: (2021)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy
por: Hu, Zhiwei, et al.
Publicado: (2016)

Untangling crises: GFC and COVID-19 through the lens of a DSGE model()
por: De La Peña, Rogelio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ce1phh7055n7q2jb7b2igegf9b